60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)-Reference-Cited by-同舟云学术

60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

Published:2013-04 Issue: Volume:58 Page:S27
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Fontaine H.,Hezode C.,Dorival C.,Larrey D.,Zoulim F.,De Ledinghen V.,Canva V.,Alric L.,Bourlière M.,Pol S.,Poynard T.,Riachi G.,Bernard P.-H.,Raabe J.-J.,Gournay J.,Métivier S.,Pawlotsky J.-M.,Samuel D.,Barthe Y.,Carrat F.,Bronowicki J.-P.

Publisher

Elsevier BV

Subject

Hepatology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tratamiento de la infección crónica por los virus de la hepatitis C y B;FMC - Formación Médica Continuada en Atención Primaria;2015-05

2. Treatment Patterns, Health Care Resource Utilization, and Costs in U.S. Patients Diagnosed with Chronic Hepatitis C Infection Who Received Telaprevir or Boceprevir;Journal of Managed Care & Specialty Pharmacy;2015-04

3. Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin;Current Hepatology Reports;2015-02-27

4. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations;Molecular BioSystems;2015

5. Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C;Annals of Hepatology;2014-09